Marvel Biosciences Corp
XTSX:MRVL
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
|
Marvel Biosciences Corp
XTSX:MRVL
|
8.3m CAD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
196.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
43.8B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
279.2B CNY |
Loading...
|
|
| DE |
|
BioNTech SE
NASDAQ:BNTX
|
25.7B USD |
Loading...
|
|
| US |
|
Incyte Corp
NASDAQ:INCY
|
20.4B USD |
Loading...
|
|
| US |
|
United Therapeutics Corp
NASDAQ:UTHR
|
20.7B USD |
Loading...
|
|
| DK |
|
Genmab A/S
CSE:GMAB
|
124.3B DKK |
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
18.4B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Marvel Biosciences Corp
Glance View
Marvel Biosciences Corp. operates as a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm is focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor. The firm has developed several new chemical entities, using synthetic chemical derivatives of known drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, including depression and anxiety, Alzheimer’s, attention deficit hyperactivity disorder (ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm is focused on the development of its lead molecule, MB-204 (Target 1b), which is in Phase I clinical trials. Its wholly owned subsidiary is Marvel Biotechnology Inc.
